RYAN ARTHUR F has demonstrated a consistent selling bias in Regeneron Pharmaceuticals (REGN) shares, with no recorded purchases across 75 transactions totaling $535,116 in sales. The activity is concentrated in REGN, the only company in which Ryan has reported trades. Recent filings show a continuation of this trend, with 21 sales since June 2024, including multiple transactions on key dates. On March 2, 2026, Ryan executed seven sales ranging from $1,556 to $15,779, collectively worth $48,955. Earlier, on February 9, 2026, another cluster of seven sales occurred, with the largest being a $44,321 transaction alongside smaller dispositions between $776 and $9,342.
The pattern extends back to June 3, 2024, when six sales were reported, including two larger transactions of $14,966 and $13,978 alongside mid-sized sales between $4,971 and $11,918. The absence of any buy transactions—coupled with periodic, multi-trade sell-offs—suggests an ongoing reduction in Ryan’s REGN holdings. While some filings from 2025 and early 2026 show acquisitions (coded "A") with no reported value, the overwhelming direction remains liquidation, with sales executed at varying scales but no offsetting purchases disclosed in the data. The transactions appear systematic, often grouped on single dates, though the exact nature of the sales—whether planned divestments or discretionary trades—is not specified in the filings.
AI-assisted summary